Novacyt SA
PAR:ALNOV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Novacyt SA
Cash from Investing Activities
Novacyt SA
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novacyt SA
PAR:ALNOV
|
Cash from Investing Activities
-£898k
|
CAGR 3-Years
35%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Cash from Investing Activities
-€1.7m
|
CAGR 3-Years
61%
|
CAGR 5-Years
38%
|
CAGR 10-Years
24%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Cash from Investing Activities
-€3.6m
|
CAGR 3-Years
57%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Cash from Investing Activities
-€133.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Cash from Investing Activities
-$1.4m
|
CAGR 3-Years
-139%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Abivax SA
PAR:ABVX
|
Cash from Investing Activities
-€8.1m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
Novacyt SA
Glance View
Novacyt SAS engages in the development and sale of cancer and infectious disease diagnostic products. The company is headquartered in Velizy-Villacoublay, Ile-De-France. The company went IPO on 2012-10-12. The firm develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The firm provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The firm develops secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The firm creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of distributors.
See Also
What is Novacyt SA's Cash from Investing Activities?
Cash from Investing Activities
-898k
GBP
Based on the financial report for Jun 30, 2025, Novacyt SA's Cash from Investing Activities amounts to -898k GBP.
What is Novacyt SA's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-5%
Over the last year, the Cash from Investing Activities growth was 94%. The average annual Cash from Investing Activities growth rates for Novacyt SA have been 35% over the past three years , -5% over the past five years .
